193 related articles for article (PubMed ID: 30591679)
1. Stemness, Pluripotentiality, and Wnt Antagonism: sFRP4, a Wnt antagonist Mediates Pluripotency and Stemness in Glioblastoma.
Bhuvanalakshmi G; Gamit N; Patil M; Arfuso F; Sethi G; Dharmarajan A; Kumar AP; Warrier S
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30591679
[TBL] [Abstract][Full Text] [Related]
2. Netrin-like domain of sFRP4, a Wnt antagonist inhibits stemness, metastatic and invasive properties by specifically blocking MMP-2 in cancer stem cells from human glioma cell line U87MG.
Yasmin IA; Mohana Sundaram S; Banerjee A; Varier L; Dharmarajan A; Warrier S
Exp Cell Res; 2021 Dec; 409(2):112912. PubMed ID: 34762897
[TBL] [Abstract][Full Text] [Related]
3. Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells.
Warrier S; Balu SK; Kumar AP; Millward M; Dharmarajan A
Oncol Res; 2013; 21(2):93-102. PubMed ID: 24406045
[TBL] [Abstract][Full Text] [Related]
4. Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.
Bhuvanalakshmi G; Arfuso F; Millward M; Dharmarajan A; Warrier S
PLoS One; 2015; 10(6):e0127517. PubMed ID: 26030909
[TBL] [Abstract][Full Text] [Related]
5. iPSC-Derived Glioblastoma Cells Have Enhanced Stemness Wnt/β-Catenin Activity Which Is Negatively Regulated by Wnt Antagonist sFRP4.
Yasmin IA; Dharmarajan A; Warrier S
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509281
[TBL] [Abstract][Full Text] [Related]
6. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.
He B; Lee AY; Dadfarmay S; You L; Xu Z; Reguart N; Mazieres J; Mikami I; McCormick F; Jablons DM
Cancer Res; 2005 Feb; 65(3):743-8. PubMed ID: 15705870
[TBL] [Abstract][Full Text] [Related]
7. Secreted Frizzled-related protein 4 (sFRP4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines.
Deshmukh A; Kumar S; Arfuso F; Newsholme P; Dharmarajan A
Sci Rep; 2017 May; 7(1):2256. PubMed ID: 28536422
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic demethylation of sFRPs, with emphasis on sFRP4 activation, leading to Wnt signalling suppression and histone modifications in breast, prostate, and ovary cancer stem cells.
Deshmukh A; Arfuso F; Newsholme P; Dharmarajan A
Int J Biochem Cell Biol; 2019 Apr; 109():23-32. PubMed ID: 30710752
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Stem-Like Cells Are Inhibited by Diosgenin, a Steroidal Saponin, by the Attenuation of the Wnt β-Catenin Signaling via the Wnt Antagonist Secreted Frizzled Related Protein-4.
Bhuvanalakshmi G; Basappa ; Rangappa KS; Dharmarajan A; Sethi G; Kumar AP; Warrier S
Front Pharmacol; 2017; 8():124. PubMed ID: 28373842
[No Abstract] [Full Text] [Related]
10. The inhibitory influence of adipose tissue-derived mesenchymal stem cell environment and Wnt antagonism on breast tumour cell lines.
Visweswaran M; Arfuso F; Dilley RJ; Newsholme P; Dharmarajan A
Int J Biochem Cell Biol; 2018 Feb; 95():63-72. PubMed ID: 29277675
[TBL] [Abstract][Full Text] [Related]
11. MeCP2 modulates the canonical Wnt pathway activation by targeting SFRP4 in rheumatoid arthritis fibroblast-like synoviocytes in rats.
Miao CG; Huang C; Huang Y; Yang YY; He X; Zhang L; Lv XW; Jin Y; Li J
Cell Signal; 2013 Mar; 25(3):598-608. PubMed ID: 23200852
[TBL] [Abstract][Full Text] [Related]
12. EZH2 regulates sFRP4 expression without affecting the methylation of sFRP4 promoter DNA in colorectal cancer cell lines.
Liu Y; Yu J; Xie Y; Li M; Wang F; Zhang J; Qi J
Exp Ther Med; 2020 Nov; 20(5):33. PubMed ID: 32952624
[TBL] [Abstract][Full Text] [Related]
13. RYK promotes the stemness of glioblastoma cells via the WNT/ β-catenin pathway.
Adamo A; Fiore D; De Martino F; Roscigno G; Affinito A; Donnarumma E; Puoti I; Ricci Vitiani L; Pallini R; Quintavalle C; Condorelli G
Oncotarget; 2017 Feb; 8(8):13476-13487. PubMed ID: 28086236
[TBL] [Abstract][Full Text] [Related]
14. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro.
Horvath LG; Henshall SM; Kench JG; Saunders DN; Lee CS; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Clin Cancer Res; 2004 Jan; 10(2):615-25. PubMed ID: 14760084
[TBL] [Abstract][Full Text] [Related]
15. Placental expression of secreted frizzled related protein-4 in the rat and the impact of glucocorticoid-induced fetal and placental growth restriction.
Hewitt DP; Mark PJ; Dharmarajan AM; Waddell BJ
Biol Reprod; 2006 Jul; 75(1):75-81. PubMed ID: 16540541
[TBL] [Abstract][Full Text] [Related]
16. Antagonizing canonical Wnt signaling pathway by recombinant human sFRP4 purified from E. coli and its implications in cancer therapy.
Ghoshal A; Ghosh SS
Mol Cell Biochem; 2016 Jul; 418(1-2):119-35. PubMed ID: 27334754
[TBL] [Abstract][Full Text] [Related]
17. The Wnt regulator SFRP4 inhibits mesothelioma cell proliferation, migration, and antagonizes Wnt3a via its netrin-like domain.
Perumal V; Dharmarajan AM; Fox SA
Int J Oncol; 2017 Jul; 51(1):362-368. PubMed ID: 28534940
[TBL] [Abstract][Full Text] [Related]
18. Secreted frizzled-related protein 4 induces gastric cancer progression and resistance to cisplatin and oxaliplatin via β-catenin dysregulation.
Chen CH; Chen CJ; Huang YC; Huang PS; Chi HC; Chuang HC; Lin MH; Huang TH; Hsu JT; Chen CY
Chemotherapy; 2023 Dec; ():. PubMed ID: 38071975
[TBL] [Abstract][Full Text] [Related]
19. Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis.
Surendran K; Schiavi S; Hruska KA
J Am Soc Nephrol; 2005 Aug; 16(8):2373-84. PubMed ID: 15944336
[TBL] [Abstract][Full Text] [Related]
20. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients.
Zhang J; Cai H; Sun L; Zhan P; Chen M; Zhang F; Ran Y; Wan J
J Exp Clin Cancer Res; 2018 Sep; 37(1):225. PubMed ID: 30208924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
